Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ensysce Biosciences Inc.

    NASDAQ: ENSC · Real-Time Price · USD
    2.19
    -0.07 (-3.10%)
    At close: May 29, 2025, 3:59 PM
    2.24
    2.25%
    After-hours: May 29, 2025, 07:58 PM EDT
    -3.10%
    Bid 2.16
    Market Cap 5.19M
    Revenue (ttm) 2.81M
    Net Income (ttm) -6.82M
    EPS (ttm) 110.31
    PE Ratio (ttm) 0.02
    Forward PE -46.4
    Analyst n/a
    Ask 2.24
    Volume 36,423
    Avg. Volume (20D) 1,731,649
    Open 2.24
    Previous Close 2.26
    Day's Range 2.13 - 2.24
    52-Week Range 1.62 - 14.67
    Beta 1.10

    About ENSC

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ENSC
    Website n/a
    Full Company Profile

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +96.26%
    Ensysce Biosciences shares are trading higher afte... Unlock content with Pro Subscription
    6 months ago
    +14.48%
    Ensysce Biosciences shares are trading higher after the company announced treatment for its first group of subjects in the PF614-MPAR-102 study.
    news image

    2 weeks ago · accessnewswire.com

    Ensysce Biosciences Reports First Quarter 2025 Financial Results

    Receives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder Clinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025...

    news image

    2 weeks ago · accessnewswire.com

    Ensysce Biosciences Bolsters Management Team with Regulatory Expert

    ~ Advanced Preparation for New Drug Application ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical...

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

    SAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain reli...

    news image

    1 month ago · benzinga.com

    Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

    Ensysce Biosciences, Inc ENSC stock gained almost 100% with a strong session volume compared to the average volume of 81.23K, as per data from Benzinga Pro.

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

    SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain reli...

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

    ~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~ ~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, In...

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

    ~ Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~ SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensy...

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for sev...

    news image

    2 months ago · accessnewswire.com

    Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

    ~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~ ~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce B...

    news image

    2 months ago · accessnewswire.com

    Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

    Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / ...

    Add to Watchlist